# US 2006/0051370 A1 · Microorganisms for therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0051370 A1
- Document ID: US20060051370A1
- Status: Published application
- Kind: A1
- Application number: 11/238,025
- Filed: 2005-09-27
- Published: 2006-03-09
- Earliest claimed: 2003-06-18
- Assignees: Genelux Corporation
- Inventors: Aladar Szalay; Tatyana Timiryasova; Yong Yu; Qian Zhang
- Web page: https://patentgrep.com/patent/US20060051370A1

## CPC

- A61K 39/285: Vaccinia virus or variola virus
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/30: from tumour cells
- C07K 16/40: against enzymes
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- C12P 19/34: Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/5256: {expressing foreign proteins}
- C12N 2710/24132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- C12N 2710/24161: Methods of inactivation or attenuation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

Therapeutic methods and microorganisms therefor are provided. The microorganisms are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organisms. The microorganisms also are designed or modified to result in leaky cell membranes of cells in which they accumulate, resulting in production of antibodies reactive against proteins and other cellular products and also permitting exploitation of proferating proliferating tissues, particularly tumors, to produce selected proteins and other products. Vaccines containing the microorganisms are provided. Combinations of the microorganisms and anti-cancer agents and uses thereof for treating cancer also are provided.

## Claims

### Claim 1

A combination, comprising:
a pharmaceutical composition, comprising a recombinant vaccina virus whose genome contains a modified thymidine kinase (TK) gene and/or a modified HA gene, and insertion, deletion or mutation in the locus designated F3; and
an anticancer agent.

### Claim 2 (depends on 1)

The combination of claim 1, wherein:
(a) the TK gene and/or HA gene is/are inactivated; and
(b) the F3 locus is inactivated

### Claim 3 (depends on 1)

The combination of claim 1, wherein inactivation of at least one of the genes or loci is effected by insertion of heterologous nucleic acid therein.

### Claim 4 (depends on 1)

The combination of claim 1, wherein heterologous nucleic acid is inerted into the TK and HA genes to inactivate them, and heterologous nucleic acid is inserted into the F3 locus.

### Claim 5 (depends on 1)

The combination of claim 1, wherein the vaccinia virus is a Lister strain.

### Claim 6 (depends on 2)

The combination of claim 2, wherein the vaccinia virus is a Lister strain.

### Claim 7 (depends on 3)

The combination of claim 3, wherein the vaccinia virus is an LIVP strain.

### Claim 8 (depends on 4)

The combination of claim 4, wherein the vaccinia virus is a LIVP strain.

### Claim 9 (depends on 8)

The combination of claim 8, wherein the modification of the F3 locus is at the NotI site within the F3 gene or at a corresponding locus.

### Claim 10 (depends on 8)

The combination of claim 8, wherein the modification of the F3 locus is at position 1475 inside of the HindIII F fragment of the nucleic acid.

### Claim 11 (depends on 3)

The combination of claim 3, wherein the at least one of the TK, HA gene and F3 locus comprises an insertion of heterologous nucleic acid that encodes a protein.

### Claim 12 (depends on 11)

The combination of claim 11, wherein the heterologous nucleic acid comprises a regulatory sequence operatively linked to the nucleic acid encoding the protein.

### Claim 13 (depends on 12)

The combination of claim 12, wherein the regulatory sequence comprises the vaccinia virus early/late promoter p7.5.

### Claim 14 (depends on 12)

The combination of claim 12, wherein the regulatory sequence comprises an early/late vaccinia pE/L promotor.

### Claim 15 (depends on 11)

The combination of claim 11, wherein the heterologous nucleic acid encodes a detectable protein or a protein capable of inducing a detectable signal.

### Claim 16 (depends on 1)

The combination of claim 1, wherein the anticancer agent is a chemotherapeutic compound.

### Claim 17 (depends on 1)

The combination of claim 1, wherein the anticancer agent is selected from among alkylating agents, antimetabolites, platinum coordination complexes, anthracenediones, substituted ureas, methylhydrazine derivatives, adrenocortical suppressants and anti-cancer polysaccharides.

### Claim 18 (depends on 1)

The combination of claim 1, wherein the anticancer agent is selected from among gancyclovir, 5-fluorouracil, 6-methylpurine deoxyriboside, cephalosporin-doxorubicin, 4-[(2-chloroethyl)(2-mesuloxyethyl)amino]benzoyl-L-glutamic acid, acetominophen, indole-3-acetic acid, CB1954, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycampotothecin, bis-(2-chloroethyl)amino-4-hydroxyphenylaminomethanone 28, 1-chloromethyl-5-hydroxy-1,2-dihyro-3H-benz[e]indole, epirubicin-glucoronide, 5′-deoxy5-fluorouridine, cytosine arabinoside, and linamarin.

### Claim 19 (depends on 1)

The combination of claim 1, wherein the compound and virus are formulated separately in two compositions

### Claim 20 (depends on 1)

The combination of claim 1, wherein the compound and virus are formulated as single composition.

### Claim 21 (depends on 2)

The combination of claim 2, wherein the anticancer agent is selected from among alkylating agents, antimetabolites, platinum coordination complexes, anthracenediones, substituted ureas, methylhydrazine derivatives, adrenocortical suppressants and anti-cancer polysaccharides.

### Claim 22 (depends on 2)

The combination of claim 2, wherein the anticancer agent is selected from among gancyclovir, 5-fluorouracil, 6-methylpurine deoxyriboside, cephalosporin-doxorubicin, 4-[(2-chloroethyl)(2-mesuloxyethyl)amino]benzoyl-L-glutamic acid, acetominophen, indole-3-acetic acid, CB1954, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycampotothecin, bis-(2-chloroethyl)amino-4-hydroxyphenylaminomethanone 28, 1-chloromethyl-5-hydroxy-1,2-dihyro-3H-benz[e]indole, epirubicin-glucoronide, 5′-deoxy5-fluorouridine, cytosine arabinoside, and linamarin.

### Claim 23 (depends on 2)

The combination of claim 2, wherein the compound and virus are formulated as single composition

### Claim 24 (depends on 1)

A kit, comprising:
a combination of claim 1 packaged as a kit; and
optionally instructions for administration thereof for treatment of cancer.

### Claim 25 (depends on 1)

A method of treatment of cancer, comprising:
administering the components of a combination of claim 1 to a subject for treatment of cancer.

### Claim 26 (depends on 2)

A kit, comprising:
a combination of claim 2 packaged as a kit; and
optionally instructions for administration thereof for treatment of cancer.

### Claim 27 (depends on 2)

A method of treatment of cancer, comprising: administering the components of a combination of claim 2 to a subject for treatment of cancer.

### Claim 28

A vaccine, comprising a comprising a recombinant vaccina virus whose genome contains a modified thymidine kinase (TK) gene and/or a modified HA gene, and an insertion, deletion or mutation in the locus designated F3.

### Claim 29 (depends on 28)

The vaccine of claim 28, wherein:
(a) the TK gene and/or HA gene is/are inactivated; and
(b) the F3 locus is inactivated

### Claim 30 (depends on 28)

The vaccine of claim 28, wherein inactivation of at least one of the genes or loci is effected by insertion of heterologous nucleic acid therein.

### Claim 31 (depends on 28)

The vaccine of claim 28, wherein heterologous nucleic acid is inerted into the TK and HA genes to inactivate them, and heterologous nucleic acid is inserted into the F3 locus.

### Claim 32 (depends on 28)

The vaccine of claim 28, wherein the vaccinia virus is a Lister strain.

### Claim 33 (depends on 28)

The vaccine of claim 28, wherein the vaccinia virus is an LIVP strain.

### Claim 34 (depends on 33)

The vaccine of claim 33, where the vaccinia virus is TK−, HA− and F3−.

### Claim 35 (depends on 34)

The vaccine of claim 34, wherein the vaccinia virus has an insertion at the NotI site in the F3 locus.

### Claim 36 (depends on 29)

The vaccine of claim 29 that is a smallpox vaccine.

### Claim 37 (depends on 34)

The vaccine of claim 34 that is a smallpox vaccine.

### Claim 38 (depends on 29)

A method of vaccination, comprising administering the vaccine of claim 29 to a subject.

### Claim 39 (depends on 34)

A method of vaccination, comprising administering the vaccine of claim 34 to a subject.

### Claim 40 (depends on 1)

The combination of claim 1, where the vaccinia virus is TK-, HA- and F3-.

### Claim 41 (depends on 1)

The combination of claims 1, wherein the vaccinia virus has an insertion at the NotI site in the F3 locus.

### Claim 42 (depends on 2)

The combination of claim 2, wherein the compound and virus are formulated separately in two compositions
